Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Teradyne, Inc. (TER) vs 10X Genomics Inc (TXG) Price & Performance

Teradyne, Inc.Trade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Teradyne, Inc. vs 10X Genomics Inc — how do they compare? Teradyne, Inc. trades at $381.9 (market cap $57.08B), while 10X Genomics Inc trades at $59.38 (market cap $7.64B). The key difference: Teradyne, Inc. is far larger — about 7.5× 10X Genomics Inc's market cap, and Teradyne, Inc. pays a 0.14% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.

TERTXG
Market Cap
$57.08B$7.64B
Sector
TechnologyHealth
52-Week High
$483.84$58.57
52-Week Low
$109.30$11.34
Enterprise Value
$56.83B$7.17B
Dividend Yield
0.14%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Teradyne, Inc.

Teradyne (TER) trades at $379.31, down 1.45% today but maintains strong technical momentum with a bullish moving average signal. The company demonstrates robust fundamentals with record Q2 2026 earnings of $2.47 EPS beating estimates by 18%, driven by AI-led semiconductor test demand. Revenue grew to $3.19 billion in 2025 with impressive 25.77% net income margin and 36.66% ROE. Analyst consensus remains strongly bullish with 64.5% buy ratings and $481.63 price target representing 27% upside potential.

Teradyne presents compelling growth prospects fueled by AI-driven semiconductor testing demand and expanding robotics business. The stock trades at premium valuations (P/E 52.1, P/S 13.43) reflecting high growth expectations. Key risks include cyclical semiconductor industry exposure and execution challenges in scaling operations. Current technical positioning near pivot point ($384) suggests potential for breakout above resistance at $396 if earnings momentum continues through Q3 2026.

10X Genomics Inc

TXG is trading at $52.03, up 14.1% in the past 24 hours, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting upward trends, while RSI levels suggest mild overbought conditions. Fundamentally, the company reported Q2 2026 revenue of $151 million, beating estimates, and has shown consistent earnings beats in recent quarters. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding its multiomics capabilities and reinforcing growth prospects.

The outlook for TXG is cautiously optimistic, driven by earnings outperformance and strategic expansions, but risks include persistent net losses and high valuation multiples. Analyst consensus is mixed with a $46 price target, indicating potential downside from current levels. Investors should weigh revenue growth against profitability challenges and monitor execution on new initiatives for sustained upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Teradyne, Inc.

Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.

Read more on TER

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG